Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rua BioscienceNZSE:RUA +2.86% 1-Year ROIIC % is 103.75 as of Jun. 2026. The stock has 5 warning signs investors should review. Among 830 Drug Manufacturers companies, Rua Bioscience ranks worse than 87.35% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Rua Bioscience's 1-Year ROIIC % for the quarter that ended in Jun. 2026 was 103.75%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Rua Bioscience's 1-Year ROIIC % or its related term are showing as below:
NZSE:RUA's 1-Year ROIIC % is ranked worse than 87.35% of 830
companies
in the Drug Manufacturers industry
Industry Median: 1.595
vs NZSE:RUA: 103.75
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Rua Bioscience 1-Year ROIIC % Related Terms
Rua Bioscience 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Rua Bioscience's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:RUA vs ZTS, UTHR, VTRS: 1-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rua Bioscience's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rua Bioscience 1-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rua Bioscience's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Rua Bioscience's 1-Year ROIIC % falls into.
Rua Bioscience's 1-Year ROIIC % for the quarter that ended in Jun. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -3.776 (Jun. 2026) - -4.053 (Jun. 2025) )
/
( 5.943 (Jun. 2026) - 5.676 (Jun. 2025) )
=
0.277
/
0.267
=
103.75%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Rua Bioscience (NZSE:RUA) has a 1-Year ROIIC % of 103.75 as of Jun. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Rua Bioscience and its competitors. According to the industry distribution chart, Rua Bioscience ranks #725 out of 830 companies in the Drug Manufacturers industry, placing it in the top 87.3%.
Is Rua Bioscience's 1-Year ROIIC % too high?
Rua Bioscience's current 1-Year ROIIC % is 103.75. The Drug Manufacturers industry median 1-Year ROIIC % is 1.60. Rua Bioscience's value of 103.75 is 6404.7% above this industry median. Based on the distribution chart, Rua Bioscience ranks #725 out of 830 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Rua Bioscience's 1-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rua Bioscience ranks #725 out of 830 companies for 1-Year ROIIC %. This places Rua Bioscience in the lower half of its industry. The industry median 1-Year ROIIC % is 1.60. Rua Bioscience's value of 103.75 is 6404.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Drug Manufacturers company?
The median 1-Year ROIIC % among Drug Manufacturers companies is 1.60, based on 830 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rua Bioscience's current 1-Year ROIIC % of 103.75 is 6404.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Rua Bioscience and its competitors. For the Drug Manufacturers industry, the median 1-Year ROIIC % is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rua Bioscience's current 1-Year ROIIC % is 103.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rua Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Rua Bioscience (NZSE:RUA) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$0.05, compared to a current price of NZ$0.04 — trading 28% below its estimated fair value. The current 1-Year ROIIC % is 103.75 and 6404.7% above the Drug Manufacturers industry median of 1.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Rua Bioscience (NZSE:RUA), the current 1-Year ROIIC % is 103.75 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Australia, Germany, and New Zealand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:RUA has been successfully added to your 
